GSK's Avodart reduces prostate cancer progression in REDEEM
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's BPH treatment Avodart (dutasteride) could be a beneficial adjunctive treatment for men with low-risk prostate cancer who choose active surveillance over standard treatments, a new study suggests.